Medical company Genentech says it has stopped enrolling ovarian cancer patients in a test for Avastin, because a higher-than-expected number of the women developed perforations in their gastrointestinal tracts.

Genentech says five of 44 patients involved in the study, 11 percent, have developed perforations as a result of taking the drug

Biotech company Genentech Inc. announces on Friday it has stopped signing-up ovarian cancer patients in a mid-stage clinical review of the medication, Avastin.

Greentech cites greater occurrences of gastrointestinal perforations than shown in previous studies of the drug as the reason

Researchers indicate women with ovarian cancer complain of symptoms up to one year before diagnosis, but doctors do not order the proper tests for the fast-growing tumor until much later

Researchers indicate women with ovarian cancer complain of symptoms up to one year before diagnosis, but doctors do not order the proper tests for the fast-growing tumor until much later

Researchers at the University of Cambridge in England announce the discovery of four new genes believed to be involved in the development of breast cancer.

After examining tissue from 53 breast cancer tumors and cells grown in the laboratory, researchers narrowed down the search for the genes that could provide a foundation for new treatments of breast cancer